Brimonidine

also known as Brimonidine Tartrate · Alphagan · CD07805/47 · Alphagan P · Lumify · Mirvaso · ALPHAGAN (brimonidine tartrate 0.2%) Allergan Pharm. Ltd · Brimo DDS · +5 more

Developed for: open-angle glaucoma · glaucoma · ocular hypertension · rosacea · presbyopia · ocular hyperemia · diabetic retinopathy · ptosis
+25 more
· age-related macular degeneration · conjunctivitis · dry eye syndrome · hand-foot syndrome · angle-closure glaucoma · borderline glaucoma · capillary malformation · chemotherapy-induced neuropathy · conjunctival disorder · corneal edema · diffuse secondary choroid atrophy · ectropion · entropion · exfoliation syndrome · eye allergy · flushing of ears and somnolence · graft versus host disease · intraoperative floppy iris syndrome · low tension glaucoma · macular degeneration · myopia · retinitis pigmentosa · rhegmatogenous retinal detachment · telangiectasis · vascular disorder
Investigated by: Allergan · Galderma R&D · LENZ Therapeutics, Inc · Alcon Research · Bausch & Lomb Incorporated · ORA, Inc.
+56 more
· Massachusetts Eye and Ear Infirmary · Ocugen · Tarian Pharma · University of Sao Paulo · Corxel Pharmaceuticals · Medical University of Vienna · Optall Vision · Padagis LLC · Uptown Eye Specialists · Wake Forest University Health Sciences · AbbVie · Actavis Inc. · Afyon Kocatepe University Hospital · BCN Peptides · Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma · Biogen · Canadian Glaucoma Clinical Research Council · Carmel Medical Center · Chicago Center for Vision Research · Chittagong Medical College · Credit Valley EyeCare · Denver Health and Hospital Authority · Derm Research, PLLC · Duke University · Eurotrials Brasil Consultores Cientificos Ltda · Eye Therapies, LLC · Fayoum University · Fundação de Apoio ao Ensino Pesquisa e Assitência do HCFMRPUSP · Galderma Brasil Ltda. · Heinrich-Heine University, Duesseldorf · Hermann Eye Center · Indiana University · Innovative Medical · Insight Eyecare Specialties, Inc. dba Vision Source Eyecare, · Istanbul Training and Research Hospital · Kukje Pharma · Laboratorios Sophia S.A de C.V. · Nanduri, Padma, M.D., FACS · Novartis Pharmaceuticals · Prairie Eye Center · Rabin Medical Center · Sengi · Sheba Medical Center · Sun Pharma Advanced Research Company Limited · Sun Yat-sen University · Tecnoquimicas · The Hospital for Sick Children · Tulane University · University Health Network, Toronto · University of California, Los Angeles · University of California, San Francisco · University of Louisville · University of Parma · Watson Laboratories, Inc. · Zagazig University · Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.

Regulatory milestones approvals, filings & regulatory actions · 3 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Approved	EU (EMA)	Mirvaso	—	2014-02-20	europa.eu ↗
Label expansion	US (FDA)	ALPHAGAN	—	2001-12-20	fda.gov ↗
Approved	US (FDA)	ALPHAGAN	—	1996-09-06	fda.gov ↗

Trials 110 · started per year

today

US approved 1996

EU approved 2014

199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 03 trials · 1 met primary
Phase 0	NCT06730516	Jun → Sep 2024	glaucoma	Zagazig University	Completed	No outcome recorded
Phase 0	NCT03825081	Jan → Sep 2019	presbyopia	Massachusetts Eye and Ear Infirmary	Unknown	No outcome recorded
Phase 0	NCT03497442	Jul 2018 → Mar 2019	alcohol-related disorders, flushing of ears and somnolence	University of California, San Francisco	Completed	Met primary
Phase 18 trials
Phase 1	NCT06270030	Mar → Apr 2024	presbyopia	Corxel Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT05936489	Jul → Oct 2023	presbyopia	LENZ Therapeutics, Inc	Completed	No outcome recorded
Phase 1	NCT05006911	Aug → Sep 2021	presbyopia	Optall Vision	Unknown	No outcome recorded
Phase 1	NCT05006898	Jun → Jul 2020	presbyopia	Optall Vision	Completed	No outcome recorded
Phase 1	NCT02967614	Dec 2016 → Dec 2017	glaucoma, ocular hypertension	Kukje Pharma	Completed	No outcome recorded
Phase 1	NCT03139708	Sep 2016 → Oct 2017	—	Wake Forest University Health Sciences	Completed	No outcome recorded
Phase 1	NCT02039765	Feb → Mar 2014	ocular hyperemia	Bausch & Lomb Incorporated	Completed	No outcome recorded
Phase 1	NCT01229410	Dec 2010 → May 2011	—	Allergan	Completed	No outcome recorded
Phase 1/21 trial
Phase 1/2	NCT00661479	Jul 2008 → Dec 2009	retinitis pigmentosa	Allergan	Completed	No outcome recorded
Phase 227 trials · 4 met primary · 1 missed
Phase 2	NCT07457671	Mar 2026 → Mar 2027 expected	hand-foot syndrome	Tarian Pharma	Not yet recruiting	No outcome recorded
Phase 2	NCT07082764	Sep 2025 → Sep 2026 overdue	chemotherapy-induced neuropathy	Tarian Pharma	Not yet recruiting	No outcome recorded
Phase 2	NCT06948357	Mar → Sep 2025 overdue	presbyopia	Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.	Recruiting	No outcome recorded
Phase 2	NCT06818058	Jan 2025 → Sep 2026 overdue	—	Tarian Pharma	Recruiting	No outcome recorded
Phase 2	NCT06365853	Jul 2024 → Jun 2026 overdue	ovarian cancer	AbbVie	Recruiting	No outcome recorded
Phase 2	NCT05431543	Aug → Dec 2022	presbyopia	LENZ Therapeutics, Inc	Completed	Met primary
Phase 2	NCT05294328	May → Aug 2022	presbyopia	LENZ Therapeutics, Inc	Completed	Met primary
Phase 2	NCT03760185	Jan 2019 → Sep 2020	intraoperative floppy iris syndrome	Denver Health and Hospital Authority	Completed	No outcome recorded
Phase 2	NCT04205201	Jun 2018 → Sep 2019	—	Chittagong Medical College	Completed	No outcome recorded
Phase 2	NCT03418727	Sep 2017 → Mar 2018	dry eye syndrome	Ocugen	Completed	No outcome recorded
Phase 2	NCT03173365	Jul 2017 → Dec 2018	hand-foot syndrome	Heinrich-Heine University, Duesseldorf	Terminated	No outcome recorded
Phase 2	NCT02214680	Oct 2015 → Aug 2016	—	Carmel Medical Center	Unknown	No outcome recorded
Phase 2	NCT02087085	May 2014 → Mar 2018	age-related macular degeneration, diffuse secondary choroid atrophy	Allergan	Terminated	Met primary
Phase 2	NCT02300129	Apr → Jun 2014	rosacea	Galderma R&D	Completed	Missed primary
Phase 2	NCT01675609	Aug → Oct 2012	ocular hyperemia	Eye Therapies, LLC	Completed	No outcome recorded
Phase 2	NCT01426867	Sep → Nov 2011	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 2	NCT01345448	Apr → Jul 2011	glaucoma	Nanduri, Padma, M.D., FACS	Unknown	No outcome recorded
Phase 2	NCT01174030	Aug → Dec 2010	rosacea	Galderma R&D	Completed	Mixed
Phase 2	NCT01080209	Feb 2010 → Feb 2014	—	Allergan	Completed	No outcome recorded
Phase 2	NCT00972374	Nov 2009 → Oct 2010	rhegmatogenous retinal detachment	Allergan	Completed	No outcome recorded
Phase 2	NCT00989014	Sep → Nov 2009	rosacea	Galderma R&D	Completed	No outcome recorded
Phase 2	NCT00693485	Sep 2008 → Jan 2011	open-angle glaucoma	Allergan	Completed	No outcome recorded
Phase 2	NCT00864838	Jun 2008 → Feb 2009	age-related macular degeneration, diabetic retinopathy	University of Sao Paulo	Completed	No outcome recorded
Phase 2	NCT00658619	May 2008 → Jun 2010	macular degeneration	Allergan	Completed	No outcome recorded
Phase 2	NCT00697541	May → Jun 2008	rosacea	Galderma R&D	Completed	No outcome recorded
Phase 2	NCT00317577	Dec 1998 → May 2004	open-angle glaucoma	Chicago Center for Vision Research	Completed	Met primary
Phase 2	NCT00804921	—	diabetic retinopathy, macular retinal edema	University of Sao Paulo	Completed	No outcome recorded

Phase 2/31 trial
Phase 2/3	NCT01726075	Feb 2013 → Nov 2015	diabetic retinopathy	BCN Peptides	Completed	No outcome recorded
Phase 329 trials · 9 met primary · 1 missed
Phase 3	NCT06045299	Sep 2023 → Aug 2024	presbyopia	Corxel Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT05815758	Apr → Sep 2023	eye allergy	Bausch & Lomb Incorporated	Completed	No outcome recorded
Phase 3	NCT05728944	Mar → Dec 2023	presbyopia	LENZ Therapeutics, Inc	Completed	Met primary
Phase 3	NCT05753189	Feb 2023 → Feb 2024	presbyopia	LENZ Therapeutics, Inc	Completed	No outcome recorded
Phase 3	NCT05656027	Dec 2022 → Dec 2023	presbyopia	LENZ Therapeutics, Inc	Completed	Met primary
Phase 3	NCT05591755	Nov 2022 → Aug 2023	conjunctivitis	Bausch & Lomb Incorporated	Completed	No outcome recorded
Phase 3	NCT05579730	Oct 2022 → Jul 2023	conjunctivitis	Bausch & Lomb Incorporated	Completed	No outcome recorded
Phase 3	NCT05360784	May → Nov 2022	ocular hyperemia	Bausch & Lomb Incorporated	Completed	Met primary
Phase 3	NCT04944290	May 2021 → Mar 2022	ocular hypertension, open-angle glaucoma	Padagis LLC	Completed	No outcome recorded
Phase 3	NCT03591874	Dec 2018 → Apr 2020	eye adnexa disorder, graft versus host disease	Ocugen	Terminated	No outcome recorded
Phase 3	NCT03785340	Dec 2018 → Feb 2019	dry eye syndrome	Ocugen	Completed	Missed primary
Phase 3	NCT03450629	Sep 2018 → Dec 2020	ocular hypertension, open-angle glaucoma	Sun Pharma Advanced Research Company Limited	Completed	Met primary
Phase 3	NCT02764411	Jun 2016 → Oct 2018	capillary malformation	The Hospital for Sick Children	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT02385240	Mar → Dec 2015	rosacea	Padagis LLC	Completed	No outcome recorded
Phase 3	NCT02289352	Jul → Dec 2014	rosacea	Actavis Inc.	Completed	Met primary
Phase 3	NCT01959243	Feb → Apr 2014	ocular hyperemia	Bausch & Lomb Incorporated	Completed	No outcome recorded
Phase 3	NCT01959230	Nov → Dec 2013	ocular hyperemia	Bausch & Lomb Incorporated	Completed	Met primary
Phase 3	NCT01885000	Jul → Nov 2013	rosacea	Galderma R&D	Completed	Mixed
Phase 3	NCT01284166	Jul 2013 → May 2014	glaucoma, ocular hypertension	Allergan	Withdrawn	No outcome recorded Stop: Enrollment
Phase 3	NCT01659853	Sep → Dec 2012	rosacea	Galderma R&D	Completed	No outcome recorded
Phase 3	NCT01355471	May → Nov 2011	rosacea	Galderma R&D	Completed	Met primary
Phase 3	NCT01355458	May → Sep 2011	rosacea	Galderma R&D	Completed	Met primary
Phase 3	NCT01297920	Mar 2011 → Jun 2012	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 3	NCT01318733	Mar 2011 → Jun 2012	rosacea	Galderma R&D	Completed	No outcome recorded
Phase 3	NCT00800423	Jan 2009 → Jan 2010	corneal edema	Rabin Medical Center	Unknown	No outcome recorded
Phase 3	NCT00168363	Jan 2005 → Aug 2006	glaucoma, ocular hypertension	Allergan	Completed	Met primary
Phase 3	NCT00652483	May → Dec 2003	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 3	NCT00061529	Jan 2003 → Jul 2004	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 3	NCT01882712	? → Sep 2015	—	Galderma R&D	Withdrawn	No outcome recorded

Phase 431 trials · 2 met primary
Phase 4	NCT07390578	Dec 2026 → Aug 2027 expected	ptosis	Duke University	Not yet recruiting	No outcome recorded
Phase 4	NCT04007276	Nov 2026 → Jun 2031 expected	open-angle glaucoma, ptosis	Tulane University	Not yet recruiting	No outcome recorded
Phase 4	NCT07690397	Jun 2026 → Jul 2027 expected	ocular hypertension, open-angle glaucoma	Tecnoquimicas	Active not recruiting	No outcome recorded
Phase 4	NCT07209410	Nov 2025 → Dec 2026 expected	glaucoma	Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,	Recruiting	No outcome recorded
Phase 4	NCT06883123	May 2025 → Apr 2026 overdue	open-angle glaucoma	Prairie Eye Center	Recruiting	No outcome recorded
Phase 4	NCT07431476	May → Aug 2025	rosacea	Istanbul Training and Research Hospital	Completed	No outcome recorded
Phase 4	NCT05480098	May 2022 → May 2024	ectropion, entropion, ptosis	University of Louisville	Withdrawn	No outcome recorded Stop: Enrollment
Phase 4	NCT04702789	Oct 2021 → Nov 2023	ocular hypertension, open-angle glaucoma	Laboratorios Sophia S.A de C.V.	Terminated	No outcome recorded
Phase 4	NCT05474716	May 2020 → Dec 2021	ocular vascular disorder, open-angle glaucoma	Fayoum University	Completed	No outcome recorded
Phase 4	NCT03959176	Jul 2019	ocular hypertension	Wake Forest University Health Sciences	Completed	No outcome recorded
Phase 4	NCT03150160	Sep → Dec 2017	glaucoma	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT02863705	Jul 2016 → Jul 2018	low tension glaucoma	Allergan	Completed	No outcome recorded
Phase 4	NCT02730871	Jun 2016 → Jul 2018	ocular hypertension, open-angle glaucoma	Alcon Research	Terminated	Met primary Stop: Enrollment
Phase 4	NCT02856919	Jun 2016 → Feb 2017	—	Galderma Brasil Ltda.	Completed	No outcome recorded
Phase 4	NCT02818816	Feb 2016 → Jan 2017	prostate cancer	University Health Network, Toronto	Completed	No outcome recorded
Phase 4	NCT02568111	Feb → Aug 2016	relapsing-remitting multiple sclerosis	Biogen	Withdrawn	No outcome recorded
Phase 4	NCT02616250	Dec 2015 → Sep 2016	rosacea	Galderma R&D	Completed	No outcome recorded
Phase 4	NCT02419508	Aug 2015 → Feb 2018	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	Met primary
Phase 4	NCT02249065	Sep 2014 → Aug 2015	rosacea	Galderma R&D	Completed	No outcome recorded
Phase 4	NCT02147691	May 2014 → Jan 2015	rosacea	Derm Research, PLLC	Completed	No outcome recorded
Phase 4	NCT03966560	Jan 2014 → Jan 2015	open-angle glaucoma	Afyon Kocatepe University Hospital	Completed	No outcome recorded
Phase 4	NCT01535768	Feb 2012 → Jun 2018	glaucoma	Credit Valley EyeCare	Unknown	No outcome recorded
Phase 4	NCT02003534	Jul 2010 → Feb 2013	ocular hypertension, open-angle glaucoma	Allergan	Completed	No outcome recorded
Phase 4	NCT01151904	Nov 2009 → Feb 2012	angle-closure glaucoma	Allergan	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT00869141	Mar 2009 → Mar 2013	glaucoma	University of California, Los Angeles	Completed	No outcome recorded
Phase 4	NCT00800540	Feb 2009 → Jan 2012	open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 4	NCT00457795	Dec 2006 → Feb 2009	ocular hypertension, open-angle glaucoma	Allergan	Completed	No outcome recorded
Phase 4	NCT00440141	Jul 2006 → Mar 2007	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 4	NCT00312416	Feb → Dec 2004	—	Medical University of Vienna	Completed	No outcome recorded
Phase 4	NCT00466479	Aug 1999 → Oct 2002	glaucoma	University of Parma	Completed	No outcome recorded
Phase 4	NCT00348400	—	glaucoma	Innovative Medical	Completed	No outcome recorded

Phase not applicable10 trials · 1 met primary
—	NCT04683159	Feb → Jul 2021	pterygium	Uptown Eye Specialists	Unknown	No outcome recorded
—	NCT04296916	Apr 2020 → Oct 2024	borderline glaucoma, myopia	Sun Yat-sen University	Unknown	No outcome recorded
—	NCT04633954	Jun → Aug 2019	cataract, conjunctival disorder	Uptown Eye Specialists	Completed	No outcome recorded
—	NCT03220490	Nov 2017 → Nov 2022	glaucoma	Sheba Medical Center	Unknown	No outcome recorded
—	NCT01105065	Mar 2010 → Sep 2012	glaucoma	Massachusetts Eye and Ear Infirmary	Completed	Met primary
—	NCT00824824	Jan 2009 → Aug 2012	glaucoma	Massachusetts Eye and Ear Infirmary	Completed	No outcome recorded
—	NCT00275756	Sep 2008 → Nov 2014	glaucoma	Medical University of Vienna	Withdrawn	No outcome recorded
—	NCT00435058	Sep 2005 → Apr 2006	glaucoma	University of Sao Paulo	Completed	No outcome recorded
—	NCT00352807	Feb → Dec 2005	cataract	Indiana University	Completed	No outcome recorded
—	NCT00121147	Sep 2003 → Oct 2005	exfoliation syndrome, ocular hypertension, open-angle glaucoma	Hermann Eye Center	Completed	No outcome recorded
Comparator or background therapy52 trials
Phase 0	NCT01144494 Comparator	Aug 2010 → Oct 2011	ocular hypertension	University of Nebraska	Completed	No outcome recorded
Phase 1	NCT05001243 Comparator	Aug 2021	presbyopia	Optall Vision	Unknown	No outcome recorded
Phase 1	NCT01687426 Comparator	Sep → Dec 2012	open-angle glaucoma	Eye Therapies, LLC	Completed	No outcome recorded
Phase 1/2	NCT02975557 Comparator	May 2016 → Apr 2017	dry eye syndrome, graft versus host disease	Sandeep Jain, MD	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT06996236 Comparator	Jul 2025 → Jul 2026 overdue	myopia	Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal	Not yet recruiting	No outcome recorded
Phase 2	NCT01863953 Comparator	Jun → Dec 2013	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 2	NCT01275105 Comparator	Jan → Mar 2011	eye allergy	Eye Therapies, LLC	Completed	No outcome recorded
Phase 2	NCT01887223 Comparator	May 2010 → Jun 2011	open-angle glaucoma	University of Sao Paulo General Hospital	Completed	No outcome recorded
Phase 2	NCT00961649 Comparator	Oct 2009 → Feb 2010	ocular hypertension, open-angle glaucoma	Alcon Research	Terminated	No outcome recorded
Phase 2	NCT01062971 Comparator	Feb 2006 → Aug 2007	ocular hypertension, open-angle glaucoma	Laboratorios Sophia S.A de C.V.	Completed	No outcome recorded
Phase 3	NCT06803654 Comparator	May → Jun 2025	ocular hyperemia	Bausch & Lomb Incorporated	Completed	No outcome recorded
Phase 3	NCT05270863 Comparator	Mar 2022 → Mar 2023	presbyopia	Visus Therapeutics	Completed	Met primary
Phase 3	NCT02339584 Comparator	Apr 2015 → Nov 2016	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 3	NCT01789775 Comparator	Dec 2012 → Oct 2013	rosacea	Galderma R&D	Completed	No outcome recorded
Phase 3	NCT01309204 Comparator	May 2011 → Jan 2013	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	Met primary
Phase 3	NCT01310777 Comparator	May 2011 → Jan 2013	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 3	NCT01241240 Comparator	Mar 2011 → Sep 2013	ocular hypertension, open-angle glaucoma	Allergan	Completed	Met primary
Phase 3	NCT01297517 Comparator	Feb 2011 → Mar 2012	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	Met primary
Phase 3	NCT01217606 Comparator	Jan 2011 → Sep 2014	ocular hypertension, open-angle glaucoma	Allergan	Completed	Met primary
Phase 3	NCT01216943 Background	Nov 2010 → Aug 2012	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 3	NCT01004900 Comparator	Jun 2009 → Mar 2011	glaucoma	Singapore Eye Research Institute	Unknown	No outcome recorded
Phase 3	NCT00651612 Comparator	Nov 2005 → Jan 2007	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 3	NCT00652106 Comparator	Jun 2003 → Mar 2004	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 4	NCT06449352 Comparator	Jun 2024 → Sep 2025	low tension glaucoma	Westlake Eye Specialists	Completed	No outcome recorded
Phase 4	NCT06369077 Comparator	Apr → Jul 2024	open-angle glaucoma	CT Glaucoma Associates	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT06078592 Comparator	Oct 2021 → Dec 2022	glaucoma, ocular hypertension	CHA University	Completed	No outcome recorded
Phase 4	NCT03782701 Comparator	Jun 2019 → Apr 2020	ptosis	University of Miami	Completed	No outcome recorded
Phase 4	NCT04647461 Comparator	Mar 2019 → Jan 2021	glaucoma, ocular hypertension	CHA University	Unknown	No outcome recorded
Phase 4	NCT03323164 Comparator	Jul 2017 → Dec 2018	low tension glaucoma	Wills Eye	Completed	No outcome recorded
Phase 4	NCT03192826 Comparator	Jun 2016 → Jul 2017	lens disorder, ocular hypertension	University Hospital of Patras	Completed	No outcome recorded
Phase 4	NCT03048058 Background	May 2016 → Jun 2017	rosacea	Wake Forest University Health Sciences	Completed	No outcome recorded
Phase 4	NCT02761174 Comparator	Mar → Jul 2016	telangiectasis	Merete Haedersdal	Completed	No outcome recorded
Phase 4	NCT01525173 Comparator	Jan → Oct 2012	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 4	NCT01446497 Comparator	Oct 2010 → Aug 2011	low tension glaucoma	Seoul National University Hospital	Unknown	No outcome recorded
Phase 4	NCT01170884 Comparator	Dec 2009 → Sep 2010	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 4	NCT00972257 Comparator	Jan → Sep 2009	open-angle glaucoma	Aristotle University Of Thessaloniki	Completed	No outcome recorded
Phase 4	NCT00811850 Comparator	Dec 2008 → Dec 2009	glaucoma	Allergan	Completed	No outcome recorded
Phase 4	NCT00811564 Comparator	Dec 2008 → Jan 2010	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 4	NCT00735449 Comparator	Jul 2008 → Dec 2009	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 4	NCT00698945 Comparator	Jun → Nov 2008	ocular hypertension, open-angle glaucoma	Bp Consulting, Inc	Completed	No outcome recorded
Phase 4	NCT00675207 Comparator	Jan 2006 → Jul 2007	ocular hypertension, open-angle glaucoma	Northwestern Ophthalmic Institute S.C.	Completed	No outcome recorded
Phase 4	NCT00347035 Background	—	glaucoma	Federal University of São Paulo	Terminated	No outcome recorded
—	NCT04523844 Comparator	May → Jul 2020	ocular hypertension	General Hospital of Athens Elpis	Completed	No outcome recorded
—	NCT03494257 Comparator	Sep 2017 → Mar 2018	cataract	University Hospital of Patras	Completed	No outcome recorded
—	NCT03513172 Comparator	Dec 2016 → Jul 2017	ocular hypertension	University of Toronto	Completed	No outcome recorded
—	NCT03508869 Comparator	Sep 2016 → Sep 2017	rosacea	Skin Laser & Surgery Specialists	Terminated	No outcome recorded
—	NCT02140450 Comparator	Feb 2012 → Jan 2014	—	Mashhad University of Medical Sciences	Completed	No outcome recorded
—	NCT01201551 Comparator	Jun 2011 → Nov 2013	vascular disorder	University Hospital, Basel, Switzerland	Completed	No outcome recorded
—	NCT01229462 Comparator	Oct 2010 → Sep 2011	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
—	NCT00712777 Comparator	Mar 2008 → Nov 2014	—	Medical University of Vienna	Withdrawn	No outcome recorded
—	NCT00402493 Comparator	Dec 2006 → Mar 2008	glaucoma, ocular hypertension	Philadelphia Eye Associates	Completed	No outcome recorded
—	NCT00567411 Comparator	Aug 2006 → Jun 2009	ocular hypertension, open-angle glaucoma	Walter Reed Army Medical Center	Unknown	No outcome recorded

News releases announcing trial results or a regulatory action · 15

Date	Issuer	Release
2025-11-20	Sun Pharma Advanced Research Company Limited	Regulatory SPARC announces Complete Response Letter Resubmission for PDP-716 NDA by Ocuvex sparc.life ↗
2024-08-27	Lupin Limited	Regulatory Lupin Receives Approval from U.S. FDA for Brimonidine Tartrate Ophthalmic Solution, 0.1% lupin.com ↗ Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Brimonidine Tartrate Ophthalmic Solution, 0.1%, to market a generic equivalent of Alphagan® P Ophthalmic Solution, 0.1%, of AbbVie Inc.
2024-08-14	Lupin Limited	Regulatory Lupin Receives Tentative Approval from U.S. FDA for Brimonidine Tartrate Ophthalmic Solution, 0.025% (OTC) lupin.com ↗
2023-10-01	Alembic Pharmaceuticals Ltd.	Regulatory Press Release USFDA Products Approval for Qtr ended 30th September 2023 alembicpharmaceuticals.com ↗ Alembic Pharmaceuticals receives various US Food & Drug Administration (USFDA) product approvals during the quarter ended 30th September, 2023.
2023-03-01	Alembic Pharmaceuticals Ltd.	Regulatory 30th March, 2023, Vadodara, India alembicpharmaceuticals.com ↗ Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Brimonidine Tartrate Ophthalmic Solution, 0.15%.
2022-10-18	LENZ Therapeutics, Inc	Results LENZ Therapeutics Announces Positive Topline Data from Phase 2 INSIGHT Trial of LNZ100 and LNZ101 to Treat Presbyopia lenz-tx.com ↗ Both LNZ100 and LNZ101 maintained statistical significance of three-line or greater improvement compared to vehicle for all timepoints including the last measured at 10 hours, 37% and 48% respectively.
2021-05-14	Sun Pharma Advanced Research Company Limited	Results SPARC Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of PDP-716 for the Treatment of Open Angle Glaucoma or Ocular Hypertension Met Pre-specified Primary Endpoint sparc.life ↗ Equivalence in intraocular pressure was demonstrated across all 9 required timepoints, showing that the 2 formulations of brimonidine are functionally equivalent.
2018-05-02	Ocugen	Results Ocugen Presents Preclinical Efficacy Data of its Proprietary Nanoemulsion Technology at ARVO 2018 ocugen.com ↗ The results highlight superior (statistically significant) efficacy of OCU300 in a surrogate mouse model of ocular graft versus host disease (oGVHD), as compared to placebo, untreated control, and marketed brimonidine.
2018-03-20	Ocugen	Results Ocugen Reports Positive Phase 2 Clinical Results Demonstrating Proof-of-Concept for its Novel Combination Therapy for Dry Eye Disease ocugen.com ↗ The randomized, multi-center, double-blinded, placebo-controlled study met its primary endpoint of tolerability over a 12-week period.
2017-09-25	Ocugen	Regulatory Ocugen Announces FDA Acceptance of Investigational New Drug Application for OCU310 (brimonidine/steroid combination therapy) and Initiates Proof of Concept Study for Treatment of Dry Eye Disease ocugen.com ↗ the U.S. Food and Drug Administration (FDA) accepted its Investigational New Drug (IND) application for OCU310 (brimonidine/steroid combination therapy), a topical formulation for the treatment of dry eye disease (DED).
2017-08-09	Ocugen	Regulatory Ocugen Receives FDA Orphan Drug Designation for OCU300 (brimonidine tartrate) for the Treatment of Ocular Graft Versus Host Disease ocugen.com ↗ We are very excited to receive the first ever orphan drug designation by the FDA for oGVHD, emphasizing the unmet medical need for patients with this disease.
2017-08-04	Perrigo Company	Regulatory Perrigo Announces Tentative FDA Approval For Generic Version Of Mirvaso® Gel perrigo.com ↗ Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Mirvaso ® (brimonidine) topical gel 0.33%.
2015-11-15	Novartis Pharmaceuticals	Results Alcon introduces Contoura Vision as first personalized LASIK procedure at American Academy of Ophthalmology Annual Meeting novartis.com ↗ Findings show additive effect of BBFC therapy in patients with open-angle glaucoma or ocular hypertension who were inadequately controlled on PGA alone.
2013-08-26	Galderma R&D	Regulatory Galderma Receives FDA Approval of Mirvaso® galderma.com ↗ Galderma Laboratories, L.P. today announced that the U.S. Food and Drug Administration (FDA) has approved Mirvaso® (brimonidine) topical gel, 0.33%* for the topical treatment of the facial erythema (redness) of rosacea in adults 18 years of age or older.
2011-10-20	Galderma R&D	Results Galderma announces positive Phase 2B Results for Investigational Compound targeting Redness of Rosacea galderma.com ↗ Galderma Pharma S.A., today announced positive top-line results from a Phase 2b trial that evaluated the efficacy and safety of CD07805/47, a proprietary topical gel under investigation for treating patients with moderate to severe facial erythema (redness) of rosacea.

All press releases naming this drug 17 releases

Date	Issuer	Release
2025-11-20	Sun Pharma Advanced Research Company Limited	SPARC announces Complete Response Letter Resubmission for PDP-716 NDA by Ocuvex sparc.life ↗
2024-08-27	Lupin Limited	Lupin Receives Approval from U.S. FDA for Brimonidine Tartrate Ophthalmic Solution, 0.1% lupin.com ↗
2024-08-14	Lupin Limited	Lupin Receives Tentative Approval from U.S. FDA for Brimonidine Tartrate Ophthalmic Solution, 0.025% (OTC) lupin.com ↗
2023-10-01	Alembic Pharmaceuticals Ltd.	Press Release USFDA Products Approval for Qtr ended 30th September 2023 alembicpharmaceuticals.com ↗
2023-03-01	Alembic Pharmaceuticals Ltd.	30th March, 2023, Vadodara, India alembicpharmaceuticals.com ↗
2022-10-18	LENZ Therapeutics, Inc	LENZ Therapeutics Announces Positive Topline Data from Phase 2 INSIGHT Trial of LNZ100 and LNZ101 to Treat Presbyopia lenz-tx.com ↗
2022-04-14	Novartis Pharmaceuticals	Sandoz launches generic brimonidine tartrate/timolol maleate eyedrop in US for patients with ocular hypertension, expanding leading ophthalmic portfolio novartis.com ↗
2021-05-14	Sun Pharma Advanced Research Company Limited	SPARC Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of PDP-716 for the Treatment of Open Angle Glaucoma or Ocular Hypertension Met Pre-specified Primary Endpoint sparc.life ↗
2018-05-02	Ocugen	Ocugen Presents Preclinical Efficacy Data of its Proprietary Nanoemulsion Technology at ARVO 2018 ocugen.com ↗
2018-03-20	Ocugen	Ocugen Reports Positive Phase 2 Clinical Results Demonstrating Proof-of-Concept for its Novel Combination Therapy for Dry Eye Disease ocugen.com ↗
2017-09-25	Ocugen	Ocugen Announces FDA Acceptance of Investigational New Drug Application for OCU310 (brimonidine/steroid combination therapy) and Initiates Proof of Concept Study for Treatment of Dry Eye Disease ocugen.com ↗
2017-08-09	Ocugen	Ocugen Receives FDA Orphan Drug Designation for OCU300 (brimonidine tartrate) for the Treatment of Ocular Graft Versus Host Disease ocugen.com ↗
2017-08-04	Perrigo Company	Perrigo Announces Tentative FDA Approval For Generic Version Of Mirvaso® Gel perrigo.com ↗
2016-08-23	Perrigo Company	Perrigo Announces Tentative FDA Approval For Generic Version Of Suprep® Oral Solution And Confirms Patent Challenge For Generic Version Of Mirvaso® Gel perrigo.com ↗
2015-11-15	Novartis Pharmaceuticals	Alcon introduces Contoura Vision as first personalized LASIK procedure at American Academy of Ophthalmology Annual Meeting novartis.com ↗
2013-08-26	Galderma R&D	Galderma Receives FDA Approval of Mirvaso® galderma.com ↗
2011-10-20	Galderma R&D	Galderma announces positive Phase 2B Results for Investigational Compound targeting Redness of Rosacea galderma.com ↗

Evidence & citations 16 cited values

Every value below carries the sentence it was read from. 167 sources stand behind the page.

Field	Value	Cited text
Known as	brimonidine	“Mirvaso® (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent facial erythema of rosacea in adults 18 years of age or older.” NCT03508869 ↗ 136 “a topical alpha agonist eye drop. (brimonidine 0.1% 1 gtts in study eye TID OR brimonidine 0.15% 1 gtts in study eye TID)” NCT01535768 ↗ “Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System” NCT01080209 ↗ “Each patient will receive the active TAR-0520 gel containing 1.5% of Brimonidine tartrate.” NCT07457671 ↗ “Brimonidine tartrate ophthalmic solution 0.025% with sodium hyaluronate (BTOS-HA)” NCT06803654 ↗ “Brimonidine Tartrate Ophthalmic Solution, 0.15% (Alphagan-P), an alpha 2 agonist” NCT00121147 ↗ “Brimonidine tartrate 2.0mg, Timolol maleate 6.8mg(without preservative)” NCT06078592 ↗ “Compare also to timolol/brimonidine/dorzolamide/bimatoprost” NCT06369077 ↗ “Brimonidine was instilled in the other eye.” NCT05006898 ↗ “brinzolamide and brimonidine tartrate” NCT06883123 ↗ “Brimonidine , Timolol” NCT02967614 ↗ Show 126 more sources
Known as	Alphagan	“first "Brimonidine", "Alphagan®" (an alpha-agonist) followed by "Timolol", "Tiloptic®" (a beta-blocker).” NCT03220490 ↗ 8 “In one group of 10 participants the left eyes will receive Alphagan prior to Tropicamide/phenylephrine.” NCT03139708 ↗ “Brimonidine 0.2 % (Alphagan, Irvine, CA, USA), dose: 1 drop per eye” NCT00712777 ↗ “Brimonidine (0.2%. alpha-2 adrenergic agonist, Alphagan®” NCT00275756 ↗ “Eyes receiving Brimonidine 0.1% (Alphagan) prior to SLT” NCT00567411 ↗ “Brimonidine(Alphagan)and Latanoprost(Xalatan) eye drops” NCT00402493 ↗ “alphagan 0.2% or alphagan-P 0.15% will be added.” NCT04296916 ↗ “Alphagan” NCT01887223 ↗ NCT00698945 ↗
Known as	ALPHAGAN (brimonidine tartrate 0.2%) Allergan Pharm. Ltd	“ALPHAGAN (brimonidine tartrate 0.2%) Allergan Pharm. Ltd” NCT03192826 ↗
Known as	Alphagan P	“OBJECTIVE: To compare the safety and intraocular pressure (IOP)-lowering effects of brimonidine-purite 0.1% with the marketed formulation of brimonidine-purite 0.15% (Alphagan...” PMID 18534052 ↗ Jun 2008 3 “Patients will be randomly assigned based on a pre-determined allocation sequence to receive topical brimonidine tartrate 0.15% (Alphagan® P; Allergan, Inc) during either the...” NCT03513172 ↗ “The purpose of this study is to test the use of a well-known eye medication (normally for treating glaucoma) called Brimonidine tartrate 0.15% (or Alphagan-P) in patients...” NCT04633954 ↗ “Brimonidine Tartrate Ophthalmic Solution, 0.15% (Alphagan-P), an alpha 2 agonist” NCT00121147 ↗
Known as	Brimo DDS	“Brimonidine Drug Delivery System (Brimo DDS), a biodegradable intravitreal implant” PMID 32134802 ↗ Jan 2021
Known as	Brimonidine Drug Delivery System	“Brimonidine Drug Delivery System (Brimo DDS), a biodegradable intravitreal implant” PMID 32134802 ↗ Jan 2021
Known as	brimonidine purite	“To evaluate the efficacy and tolerability of brimonidine purite 0.1% in comparison to brinzolamide 1% when used as adjunctive therapy to latanoprost 0.005% in patients with...” PMID 18402717 ↗ Apr 2008
Known as	Brimonidine tartarate	“Drug: Brimonidine tartarate” NCT00864838 ↗
Known as	Brimonidine Tartrate	“The purpose of this study is to test the use of a well-known eye medication (normally for treating glaucoma) called Brimonidine tartrate 0.15% (or Alphagan-P) in patients...” NCT04633954 ↗ 29 “The purpose of this study is to evaluate the safety and efficacy of brimonidine tartrate 0.025% ophthalmic solution used four times daily in a population of adult and geriatric subjects” NCT01675609 ↗ “the alpha2-adrenergic agonist brimonidine tartrate 0.2% to the beta-adrenergic antagonist timolol maleate 0.5% in preserving visual function in low-pressure glaucoma.” PMID 21257146 ↗ Jan 2011 “One drop of brimonidine tartrate ophthalmic solution (Alphagan®) administered to the affected eye(s) twice daily (morning and evening) for four weeks.” NCT01229462 ↗ “Brimonidine tartrate has a vasoconstrictive effect, which helps to reduce the amount of blood flow and hyperemia to the eye.” NCT04683159 ↗ “Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System” NCT01080209 ↗ “0.15% Brimonidine Tartrate (Alphagan® P) 1 drop in the affected eye 3 times daily for 3 months.” NCT02003534 ↗ “Brimonidine Tartrate Ophthalmic Solution, 0.15% (Alphagan-P), an alpha 2 agonist” NCT00121147 ↗ “Brimonidine tartrate 2mg/mL One drop/eye administered twice a day.” NCT01726075 ↗ “brimonidine tartrate ophthalmic solution 0.2% in each eye” NCT01863953 ↗ “Brimonidine tartrate ophthalmic solution 0.025%” NCT03782701 ↗ Show 19 more sources
Known as	Brimonidine Tartrate PS DDS	“Brimonidine Tartrate PS DDS®” NCT01229410 ↗
Known as	BTOS-PF 0.025%	“A BAK-free formulation of LUMIFY 0.025% (BTOS-PF 0.025%) could offer a solution for BAK-sensitive patients.” PMID 40711722 ↗ Jul 2025
Known as	CD07805/47	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01355471 ↗ 8 NCT01355458 ↗ NCT01882712 ↗ NCT01174030 ↗ NCT02300129 ↗ NCT00989014 ↗ NCT01659853 ↗ NCT01789775 ↗ NCT01318733 ↗
Known as	Lumify	“Lumify® (brimonidine tartrate ophthalmic solution 0.025%). Participants will instill 1 drop of the assigned investigational drug in each eye 4 times a day approximately 4 hours...” NCT05360784 ↗ 2 “Patients experiencing hyperemia greater than grade 2 on Efron scale will receive brimonidine tartrate (Lumify).” NCT07209410 ↗ “Brimonidine 0.025% (Lumify)” NCT07390578 ↗
Known as	Mirvaso	“Reference Product Mirvaso® (Brimonidine) Topical Gel, 0.33% (Galderma Laboratories, L.P., USA)” NCT02289352 ↗ 1 NCT03508869 ↗
Action	Activate	“Brimonidine Tartrate Ophthalmic Solution, 0.15% (Alphagan-P), an alpha 2 agonist” NCT00121147 ↗
Route	Topical	“dose: 1 drop in one eye twice daily for two weeks” NCT00275756 ↗